Kisqali Femara Co-pack
Product Images NDC 0078-0923

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Kisqali Femara Co-pack (NDC 0078-0923). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Kaplan-meier Progression Free Survival Curves – Monaleesa-2 (intent-to-treat Population) (Figure1)

A Kaplan-Meier survival curve chart showing event-free probability (%) over time (months) comparing Ribociclib (N=334) and Placebo (N=334). The chart includes symbols indicating censoring times for both groups, with Ribociclib represented by a solid line and Placebo by a dotted line.*

FDA Label Image

Figure 2 Kaplan-meier Progression Free Survival Curves – Monaleesa-7 (nsai, Investigator Assessment) (Figure2)

A survival curve graph comparing event-free probability (%) over time (months) for Ribociclib and Placebo groups, showing censoring times and patient numbers at risk at various intervals. The graph illustrates the probability trends and patient follow-up data through nearly 30 months.*

FDA Label Image

Figure 3 Kaplan-meier Overall Survival Curves- Monaleesa-7 (nsai) (Figure3)

A Kaplan-Meier curve graph depicting event-free probability (%) over time in months for two groups: Ribociclib (N=248) and Placebo (N=247). The graph plots event-free probability decreasing over approximately 45 months, with censored data points indicated by symbols for each group. Below the graph, a table shows the number of patients still at risk at various time points for each group.*

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets200 mg Daily Dose (one 200 mg Tablet) 21 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0909-61rx Only (Kisqali Femara 01)

KISQALI FEMARA CO-PACK packaging label showing ribociclib 200 mg tablets and letrozole 2.5 mg tablets. The package contains 21 film-coated tablets of ribociclib and 28 film-coated tablets of letrozole. The label includes dosing information indicating daily doses and instructions. Manufactured by Novartis Pharmaceuticals Corporation, the label also displays NDC codes and storage instructions.*

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets400 mg Daily Dose (two 200 mg Tablets) 42 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0916-61rx Only (Kisqali Femara 02)

KISQALI FEMARA CO-PACK packaging label showing a combination of ribociclib and letrozole tablets. The label states 400 mg daily dose (two 200 mg tablets) ribociclib with 42 film-coated tablets, and 2.5 mg per tablet letrozole with 28 film-coated tablets. It is distributed by Novartis Pharmaceuticals Corporation and includes dosage instructions, storage information, and a dosing calendar. The carton contains multiple blister packs of Kisqali and one bottle of Femara tablets.*

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets600 mg Daily Dose (three 200 mg Tablets) 63 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0923-61rx Only (Kisqali Femara 03)

Packaging label for KISQALI FEMARA CO-PACK containing ribociclib and letrozole tablets. The label indicates a 28-day supply with 63 film-coated tablets of ribociclib (600 mg daily dose as three 200 mg tablets) and 28 film-coated tablets of letrozole (2.5 mg per tablet). The product is labeled by Novartis Pharmaceuticals Corporation and includes dosage and storage information on the carton.*

FDA Label Image

Letrozole Structure (Letrozole Structure)

Chemical structure of an active ingredient depicted in the KISQALI FEMARA CO-PACK product, showing two benzene rings each with a cyano group (–CN) attached, connected to a central nitrogen-containing heterocyclic ring.*

FDA Label Image

Ribociclib Structure (Ribociclib Structure1)

Chemical structure diagram showing molecular formulas for active ingredients in KISQALI FEMARA CO-PACK, including the structures of ribociclib and letrozole components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.